Published in Viruses on August 18, 2010
Molecular mechanisms of hepatic apoptosis. Cell Death Dis (2014) 1.21
Lipids and HCV. Semin Immunopathol (2012) 1.19
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology (2014) 0.93
Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother (2013) 0.90
Hepatocyte nuclear factor 4α and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus. J Virol (2013) 0.84
Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorg Med Chem Lett (2015) 0.78
Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorg Med Chem Lett (2015) 0.77
New hepatitis C virus drug discovery strategies and model systems. Expert Opin Drug Discov (2012) 0.76
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science (1999) 24.31
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A (2005) 14.78
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med (2009) 12.07
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med (2007) 6.05
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J (1996) 5.47
Unravelling hepatitis C virus replication from genome to function. Nature (2005) 5.25
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem (2003) 4.58
Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol (2002) 4.55
Molecular biology of flaviviruses. Adv Virus Res (2003) 4.39
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol (2004) 3.53
Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med (2002) 3.49
Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology (2006) 3.44
The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol (2005) 3.35
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
Visualizing hepatitis C virus infections in human liver by two-photon microscopy. Gastroenterology (2009) 3.07
CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A (2004) 3.01
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol (2006) 2.88
Formation of native hepatitis C virus glycoprotein complexes. J Virol (1997) 2.87
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J Virol (2006) 2.48
The role of the high-density lipoprotein receptor SR-BI in the lipid metabolism of endocrine and other tissues. Endocr Rev (2003) 2.47
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog (2010) 2.28
Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol (2004) 2.26
The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov (2007) 2.24
Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology (2008) 1.82
Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology (2009) 1.72
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol (2000) 1.65
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J Virol (2007) 1.61
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A (2004) 1.48
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol (2010) 1.37
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog (2009) 1.36
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem (2006) 1.32
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol (2006) 1.31
Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol (2009) 1.22
Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. Virology (2005) 1.22
Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology (2009) 1.12
Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol (2009) 1.11
Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs (2009) 1.08
Review article: investigational agents for chronic hepatitis C. Aliment Pharmacol Ther (2009) 1.02
Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry. J Virol (2010) 1.00
The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int (2008) 0.98
New therapies for hepatitis C. Hepatology (2007) 0.90
Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol J (2006) 0.89
Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J Clin Endocrinol Metab (2002) 0.87
Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Front Biosci (Landmark Ed) (2009) 0.86
Screening of small-molecule compounds as inhibitors of HCV entry. Methods Mol Biol (2009) 0.79
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci U S A (2006) 3.69
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics. PLoS Pathog (2010) 2.48
Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A (2010) 2.44
Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog (2009) 1.73
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
Genetic mosaic analysis reveals that GATA-4 is required for proper differentiation of mouse gastric epithelium. Dev Biol (2002) 1.22
Genetic mosaic analysis indicates that the bulb region of coat hair follicles contains a resident population of several active multipotent epithelial lineage progenitors. Dev Biol (2002) 1.00